期刊
CLINICAL BIOCHEMISTRY
卷 46, 期 10-11, 页码 933-936出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2013.03.019
关键词
miRNA; Biomarkers; Pancreatic cancer
To date, pancreatic cancer (PDAC) can't be diagnosed early. Consequently, a majority of patient (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of 4 to 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are desperately needed to help alleviate the dismal prognosis of this disease. In this chapter, we review the translational studies demonstrating that miRNAs, alone or in combination, may soon translate into clinical applications as long-awaited screening tools for PDAC. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据